Abstract:
ObjectiveTo explore the correlation between blood D-dimer (D-D) level and clinicopathological characteristics of breast cancer patients, in order to provide possible clinical evidence for the diagnosis, disease progression and prognosis evaluation of breast cancer patients.
MethodsFifty-four breast cancer patients were selected as the malignant tumor group by random number table method, and 54 patients with benign breast lesions during the same period were randomly selected as the benign lesion group.All patients were drawn with venous blood at the time of admission to the hospital to detect the level of D-D in the blood.The expression of ER, PR, Her-2 and Ki-67 in breast cancer specimens was obtained from the hospital pathological diagnosis report.The differences in the level of D-D between the malignant tumor group and the benign lesion group were analyzed, and the relationship between the level of D-D and their clinicopathological characteristics of breast cancer patients in malignant tumor group were studied.
ResultsThe level of D-D in the malignant tumor group was significantly higher than that in the benign lesion group(P < 0.01).The D-D level in patients with lymph node metastasis was higher than that without metastasis (P < 0.05).There was no significant difference between the D-D level of the patients TNM stage Ⅰ and stage Ⅱ(P>0.05);stage Ⅲ was higher than stage Ⅰ and stage Ⅱ(P < 0.05).Ki-67 high-expression D-D values were higher than low-expression (P < 0.05), but there was no difference between low-expression and medium-expression, medium-expression and high-expression(P>0.05).There was no significant difference in the D-D level of different expressions of ER, PR and Her-2 in immunohistochemistry (P>0.05).
ConclusionsThe elevated level of D-D is associated with breast cancer TNM stage, lymph node metastasis and Ki-67 expression.It is suggested that the detection of D-D level in breast cancer patients be used as one of the auxiliary indicators for diagnosis, condition and prognosis evaluation.